Ionis Pharmaceuticals (IONS) Non-Current Debt (2009 - 2025)

Ionis Pharmaceuticals' Non-Current Debt history runs 17 years deep, the most recent figure standing at $28.1 million for Q4 2025.

• In Q4 2025, Non-Current Debt fell 45.85% year-over-year to $28.1 million; the TTM figure through Dec 2025 stood at $28.1 million (down 45.85% YoY), while the FY2025 annual figure was $28.1 million, down 45.85% from the prior year.
• Non-Current Debt was $28.1 million for Q4 2025 at Ionis Pharmaceuticals, down from $51.9 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $60.0 million in Q2 2021 to a low of $8.8 million in Q1 2023.
• Historically, Non-Current Debt has averaged $41.1 million across 5 years, with a median of $46.9 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Non-Current Debt jumped 298.61% in 2021, then sank 85.18% in 2023.
• A 5-year view of Non-Current Debt shows it stood at $59.7 million in 2021, then sank by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then increased by 24.11% to $51.9 million in 2024, then tumbled by 45.85% to $28.1 million in 2025.
• The last three Non-Current Debt figures came in at $28.1 million (Q4 2025), $51.9 million (Q4 2024), and $41.8 million (Q4 2023), per Business Quant data.